Corcept Therapeutics Inc
1CORT
Company Profile
Business description
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Contact
101 Redwood Shores Parkway
Redwood CityCA94065
USAT: +1 650 327-3270
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
500
Stocks News & Analysis
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,243.00 | 9.00 | 0.10% |
CAC 40 | 7,703.90 | 58.70 | -0.76% |
DAX 40 | 23,902.21 | 137.71 | -0.57% |
Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
FTSE 100 | 9,187.34 | 29.48 | -0.32% |
HKSE | 25,077.62 | 78.80 | 0.32% |
NASDAQ | 21,455.55 | 249.61 | -1.15% |
Nikkei 225 | 42,718.47 | 110.32 | -0.26% |
NZX 50 Index | 12,930.73 | 27.65 | 0.21% |
S&P 500 | 6,460.26 | 41.60 | -0.64% |
S&P/ASX 200 | 8,973.10 | 4.10 | 0.05% |
SSE Composite Index | 3,857.93 | 14.33 | 0.37% |